With the widespread adoption of population-based breast cancer screening, ductal
carcinoma in situ (DCIS) has come to represent 20–25% of all breast neoplastic lesions …

Several evidences support the concept that cancer development and progression are not
entirely cancer cell-autonomous processes, but may be influenced, and possibly driven, by …

Background & Aims Hepatocellular carcinoma (HCC) is a common cancer worldwide and
remains a major clinical challenge. Ketoconazole, a traditional antifungal agent, has …

Ductal carcinoma in situ (DCIS) is an often-diagnosed breast disease and a known, non-
obligate, precursor to invasive breast carcinoma. In this review, we explore the clinical and …

Radiotherapy is one of the most common treatment modalities for controlling a wide range of
tumors. However, it has been shown that radiotherapy alone is unable to completely …

The medicinal use of aspirin stretches back to ancient times, before it was manufactured in
its pure form in the late 19th century. Its accepted mechanistic target, cyclooxygenase (COX) …

We performed a systematic review with meta-analyses to summarize current knowledge on
prognostic factors for invasive disease after a diagnosis of ductal carcinoma in situ (DCIS) …

Cholangiocarcinoma (CCA) is a rare, but highly malignant primary hepatobiliary cancer with
a very poor prognosis and limited treatment options. Our recent studies reported that …

Background Understanding the molecular alterations associated with breast cancer (BC)
progression may lead to more effective strategies for both prevention and management. The …

Ductal carcinoma in situ (DCIS) represents pre-invasive breast carcinoma. In untreated
cases, 25–60% DCIS progress to invasive ductal carcinoma (IDC). The challenge lies in …